Search Results - cb3xxx

4 Results Sort By:
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 7/25/2024   |   Inventor(s): Christopher Bachran, Stephen Leppla
Keywords(s): Anthrax, AnthraxToxins, CB1BXX, CB1XXX, CB3CXX, CB3XXX, CBXXXX, CXXXXX, fusion proteins, Patent Category - Biotechnology, THERAPY, toxin, tumor
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Application > Therapeutics
A3 Adenosine Receptor Agonists to Treat Chemotherapy-induced Peripheral Neuropathy
This invention claims species-independent agonists of A3AR, specifically (N)-methanocarba adenine nucleosides and related pharmaceutical compositions. The A3 adenosine receptor (A3AR) subtype has been linked with helping protect the heart from ischemia, controlling inflammation, and regulating cell proliferation. Agonists of the human A3AR subtype...
Published: 4/8/2024   |   Inventor(s): Dilip Tosh, Kenneth Jacobson
Keywords(s): 2-Arylethynyl, A3, ADENOSINE, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Design, N-Methanocarba, Nucleosides, Receptor-Selective, Structure-based
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics
Pyruvate Kinase M2 Activators for the Treatment of Cancer
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 7/25/2024   |   Inventor(s): Min Shen, Craig Thomas, Douglas Auld, Matthew Boxer
Keywords(s): [1, [b], 2, 2-oxo-1, 3, 3-oxo-3, 4], 4-dihydroquinoline-2H-benzo, 4-tetrahydroquinoline-6-sulfonamides, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, Human, Kinase, MOLECULE, Oxazine-7-sulfonamides, Patent Category - Chemistry, PYRUVATE, Small, Substituted
Category(s): Collaboration Sought > Collaboration, Application > Therapeutics, TherapeuticArea > Oncology
Small Molecule Activators of Human Pyruvate Kinase for Treatment of Cancer and Enzyme-Deficient Hemolytic Anemia
NIH investigators have discovered a series of small compounds with the potential to treat a variety of cancers as well as hemolytic anemia. Contrary to most cancer medications, these molecules can be non-toxic to normal cells because they target a protein specific to the metabolic pathways in tumors, thus representing a significant clinical advantage...
Published: 7/25/2024   |   Inventor(s): Craig Thomas
Keywords(s): 3-@hydroxyacyl-coa dehydrogenase deficiency, ACTIVATORS, CB3CXX, CB3XXX, CBXXXX, CXXXXX, HAD deficiency, HIS deficiency, Histidinemia, Human, Kinase, MOLECULE, Patent Category - Chemistry, PYRUVATE, Small
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
© 2024. All Rights Reserved. Powered by Inteum